6 news items
Where Maravai LifeSciences Stands With Analysts
MRVI
9 May 24
of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
MRVI
18 Apr 24
with custom mRNA synthesis, supported 350+ programs in biopharma development pipelines, and delivered over 100 GMP mRNA manufacturing batches
Small-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 Guidance
MRVI
23 Feb 24
forecasted demand for our Nucleic Acid Production products, including for CleanCap and custom chemistry,” said Trey Martin, Chief Executive Officer
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
MRVI
22 Feb 24
, including for CleanCap and custom chemistry," said Trey Martin, Chief Executive Officer of Maravai. "Thanks to our team's strong execution, the cost
TriLink BioTechnologies, A Maravai LifeSciences Company Solidifies IP Position With Awarded Patents For CleanCap Capping Technology In China And Canada
MRVI
21 Feb 24
*Data and customer insights garnered from a market assessment conducted by a third-party consulting firm on behalf of TriLink BioTechnologies in November 2022.
ytj1bnmncv339v10v67p0tn4mtf847e2jpixuf4gbk v3f8qxaqrgclcdh
DYAI
MRVI
13 Feb 24
). Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers
- Prev
- 1
- Next